The Narayana Health Q2 results FY27 are a financial update from a group that began as a cardiac specialist, so they invite a clinical question: what do headline revenue and margin numbers tell us, and not tell us, about the care the group delivers? On 30 October 2026 the company reported consolidated operating revenue of ₹2,844 crore, up 73%, largely because a UK hospital business is now consolidated. This article reads the figures with an evidence-minded eye, labels our own calculations, and is news reporting and not medical or investment advice.
Narayana Health Q2 results FY27: key takeaways
- Consolidated revenue rose 73% to ₹2,844 crore; excluding the UK business it rose 22.6% to ₹2,015.6 crore.
- By our own subtraction, the UK business contributed about ₹828 crore.
- EBITDA was ₹605.4 crore with a margin of 21.3%, down from 25.9%; profit after tax rose 16.6% to ₹301.2 crore.
- India hospitals revenue rose 16.6% to ₹1,440.2 crore, with international patient revenue up 75.7%.
- The filings do not report clinical outcomes, so the results cannot be used to judge quality of care.
What the Narayana Health Q2 results FY27 can and cannot show
Revenue and margin describe the business. They do not describe survival after cardiac surgery, infection rates or readmissions. A group can post strong profit with excellent outcomes, or with poor ones, and the financial statement alone does not separate the two. Readers who want to judge care should look for published outcome data, accreditation status and independent audits, none of which is part of these results.
Cardiac and complex care behind the Narayana Health Q2 results FY27
The World Health Organization describes cardiovascular diseases as the leading cause of death globally, which is why hospital groups with strong cardiac programmes see steady demand. The sources we reviewed for these results do not give a breakdown by specialty, so we cannot say how much of the revenue comes from cardiac care. Visit the company website for its services.
International patients in the Narayana Health Q2 results FY27
International patient revenue in the India hospitals rose 75.7%, according to the reported figures. That indicates more patients travelling to India for treatment, or higher spending per such patient, but the sources do not say which. Medical travel raises questions about continuity of care after patients return home, such as follow-up, medication supply and handling of complications, which providers address in different ways.
The UK business in the Narayana Health Q2 results FY27
The group completed the acquisition of a UK hospital business, announced in October 2025 for a reported price of about ₹2,200 crore, per press reports. The UK business has a lower margin than India. Management said the margins reflect separation-related costs that it expects to normalise. Clinically, an acquisition can bring changes to systems, staffing and procedures, and quality teams typically monitor the transition. The sources describe no clinical changes.
Margins and what they imply in the Narayana Health Q2 results FY27
Excluding the UK, EBITDA was ₹545.2 crore, up 27.8%, with a margin of about 27%. India hospitals reached a margin of 26.8%, up from 23.8%. From an evidence viewpoint, higher margins can reflect efficiency, case mix, pricing or occupancy. Without outcome data they cannot be read as good or bad for patients. The Cayman insurance business narrowed its losses, per management.
What patients can check beyond the Narayana Health Q2 results FY27
Patients choosing a hospital can look for accreditation, the volume of the specific procedure the hospital performs, the experience of the treating team and the hospital’s approach to second opinions. Procedure volume matters because, for many complex operations, centres that perform more of them tend to be associated with better results, although this varies by procedure and no single number settles the choice.
International patients should also ask about the arrangements for follow-up in their home country and what happens if a complication arises after they return.
Scenarios after the Narayana Health Q2 results FY27
- Integration goes smoothly: UK separation costs fall, systems are aligned and the group margin improves.
- Integration is bumpy: transition costs continue and the UK business weighs on group margins for longer.
- Disclosure improves: the group publishes more quality data, giving patients something to compare.
These are our own illustrative scenarios and not forecasts.
Market context from Acumen Research and Consulting
We did not find an Acumen report on hospital services. A related equipment report, Acumen Research and Consulting’s Hospital Beds Market, values that segment at USD 3.6 billion in 2022 and projects USD 7.2 billion by 2032, a CAGR of 7.2%. It points to investment in hospital capacity, not to any operator’s clinical performance. The page was last updated in March 2023, so use it as indicative.
Questions clinicians and patients may ask about the Narayana Health Q2 results FY27
Does the group publish outcome data? How is quality monitored after the acquisition? How are international patients followed up? The sources do not say. See the filings on NSE for audited financial numbers, and our healthcare services section for related coverage.
Timeline of the Narayana Health Q2 results FY27
- October 2025: UK acquisition announced, per press reports.
- 30 September 2026: quarter ends.
- 30 October 2026: results announced.
General background: financial results and quality of care
Research on hospital performance usually relies on outcome measures such as risk-adjusted mortality and infection rates. Financial results complement them but do not replace them.
Our analysis of the Narayana Health Q2 results FY27
In our assessment, the Narayana Health Q2 results FY27 show a financially strong Indian business and a larger, lower-margin group after the UK deal. They are silent on the question patients care about most: outcomes.
What is not disclosed in the Narayana Health Q2 results FY27 coverage
- Clinical outcome data.
- Revenue by specialty.
- Occupancy and guidance.
Risks and caveats
These figures come from the company’s results as summarised in secondary reports. We did not review the full filing. The UK contribution is our own subtraction. This article is not medical or investment advice.
What to watch next
- Publication of quality indicators.
- UK margin trend.
- International patient growth.
FAQ
What was Narayana Health’s Q2 FY27 revenue?
₹2,844 crore, up 73%.
Why is the India-only figure lower?
The 73% includes the UK business; excluding it growth was 22.6%.
Do the results show care quality?
No. They report financial performance, not clinical outcomes.
How we reported this: we relied on company results as summarised in press coverage, public exchange pages, a WHO fact sheet and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 2 November 2026. This is news reporting and not advice.
